Dr. Ku was the Head of Early Pharmaceutical Development at Wyeth/Lederle (now Pfizer), overseeing discovery interface through clinical proof of concept. During her 20-year tenure, she oversaw new drug development for over 170 new clinical leads resulting in 85 original NME IND filings. She also developed 8 commercial products including Suprax, Zosyn/Tazocin, Zebeta, Isovorin, Thioplex, Sonata, Tygacil and Bosulif, three of which are antibiotics. Zosyn, in particular, remains as one of the three lifesaving injectable antibiotics in the hospital worldwide. She was in charge of a penem facility and has early exposure to carbapenems via participation in the development of Biapenem with Lederle Japan/Takeda. Sherry often leads the effort in New Drug Application and is responsible for FDA PAI activities. In 2009, Dr. Ku joined TWi Pharma as their Chief Scientific Officer and President, filing 6 high barrier ANDAs and establishing a pipeline of 6 new drugs which included 3 biologic drugs. In 2012 she co-founded Ruen Huei Biopharmaceutical Company and served as the company’s President. In 2014, Sherry Ku joined Savior Lifetec Corporation, and now serves as the Chief Executive Officer.
Dr. Ku received her B.S. in Pharmaceutical Chemistry from National Taiwan University. She then earned a Ph.D. in Pharmaceutical Chemistry at the Ohio State University.